The coronavirus pandemic highlights the need to make new medical countermeasures available on a large scale much more quickly than ever before. NIIMBL, through its major member biopharmaceutical manufacturing companies, has established a vision that there is a significant opportunity to transform CMC (chemistry, manufacturing, and controls) development and manufacturing through end-to-end integration and technology advancement. A NIIMBL-led program has already been initiated in this area, and the work has been accelerated to a degree with the investment made through the CARES Act which enabled NIIMBL to move faster toward the procurement of assets needed to establish the testbed. We will further accelerate the effort, and increase the industrial relevance, of this Process Intensification (PI) Testbed Workstream using American Rescue Plan investment to help the program realize benefits faster. The testbed will use state-of-the-art technology for process equipment, sensors and control, and it will be flexible so that new unit operations, sensors and controls can be tested using a standard process.
Physical demonstration of intensified processing that uses currently available technology now and adapts to keep on the cutting edge in the future.
Interactions among companies and stakeholders will create shared understanding that will positively impact our domestic manufacturing capabilities for medical countermeasures and vaccines in response to any future coronavirus pandemic.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.